Cybin Inc. announced the appointment of senior clinical team leaders. Cybin has strengthened its clinical and R&D team with the recent addition of senior team members: Dr. Mirza Rahman, M.D., M.P.H., FACPM, Senior Vice President, Patient Safety & Pharmacovigilance. Dr. Rahman has over 25 years of experience in the pharmaceutical industry, primarily in Pharmacovigilance, but also in Clinical Development, Medical Affairs, Pharmacoeconomics, Manufacturing, and Regulatory Affairs.

Previously, Dr. Rahman served in leadership positions at global healthcare companies including Organon and Otsuka Pharmaceuticals, where he played an integral role in leading pharmacovigilance strategy and prioritizing patient safety. Dr. Rahman is board-certified in Public Health & General Preventive Medicine and serves as the President of the American College of Preventive Medicine. In addition, he is an Adjunct Associate Professor at both Columbia University & the University of Guyana.

Atul R. Mahableshwarkar M.D., DLFAPA, Senior Vice President, Clinical Development. Dr. Mahableshwarkar is leading the CYB003 program, Cybin?s proprietary deuterated psilocybin analog program in development for the adjunctive treatment of MDD. Dr. Mahableshwarkar is a board-certified psychiatrist and accomplished drug development executive with experience in both large global and small startup pharmaceutical companies.

He brings varied experiences from academia and industry as a site principal investigator for industry-sponsored studies and has submitted several INDs and NDAs leading to drug approvals. Dr. Tom Macek, Pharm.D., Ph.D., Senior Vice President, Clinical Development. Dr. Macek is leading the CYB004 program, Cybin?s proprietary deuterated DMT program in development for the treatment of Generalized Anxiety Disorder.

Dr. Macek brings decades of pharmaceutical industry experience in new drug development across all phases of research (pre-IND to post-approval) across diverse treatment modalities and has submitted or supported several INDs and NDAs/BLAs leading to drug approvals.